Comparative Evaluation of Bone Marrow Aspirate with Trephine Biopsy in Hematological Disorders and Determination of Optimum Trephine Length in Lymphoma Infiltration

Surbhi Goyal, Usha Rani Singh and Usha Rusia

Department of Pathology, University College of Medical Sciences, Dilshad Garden, Delhi, India

Correspondence to: Dr. Surbhi Goyal MD, DNB. Senior resident, Department of Pathology, University College of Medical Sciences, University of Delhi. Dilshad garden, Delhi-110095. Tel: 91-9873896416. E-mail: dr.surbhi4you@gmail.com

Competing interests: The authors have declared that no competing interests exist.

Abstract. Introduction: Bone marrow examination is an indispensable diagnostic tool to evaluate neoplastic and non neoplastic hematological diseases. Aims: To compare bone marrow aspirate with trephine biopsy in hematological disorders. To determine the optimum trephine pre-processing length in lymphoma infiltration. Methods: Diagnostic comparison was done between simultaneous bone marrow aspirates and trephine biopsies in 449 patients. Biopsies were fixed in formalin, decalcified in 5.5% EDTA and routinely processed. Concordance rates and validity parameters for aspirate were calculated. Three deeper sections of trephine biopsy, cut at 0.1–0.2 mm intervals, were assessed for lymphoma involvement. Proportion of biopsies showing marrow infiltration by lymphoma cells was plotted against trephine length and correlation was assessed. Results: Aspirate had a high sensitivity for acute leukemia (89.4%) and multiple myeloma (88.5%), moderate for NHL (67.6%) and nonhematopoietic metastases (58.3%) and low for aplastic anemia (38.5%) and Hodgkin lymphoma (5%). Aspirate has no role in granulomatous myelitis and myelofibrosis. Lymphoma positivity increased with trephine length, with maximum positivity (68.9%) seen in 17-20 mm group and no further gain beyond 20 mm. (lymphoma positivity ≤16mm=40.3% and ≥17mm=66.1%, p=0.0011). Conclusion: Aspirate has a high specificity; its sensitivity depends upon the type of disease. Apart from few conditions, in which aspirate alone is sufficient, biopsy is mandatory in most. Preprocessing trephine length of 17-20 mm examined at multiple deeper levels was found optimal for assessing lymphoma positivity.
It is also valuable for follow up of patients undergoing chemotherapy and bone marrow transplantation. Involvement of marrow by metastases has a significant impact on patient management and prognosis. Bone marrow examination serves to establish or confirm a primary diagnosis of lymphoma or to determine the extent of disease dissemination for staging purposes. Rarely, bone marrow examination has been useful in detecting non-hematopoietic malignancy in clinically unsuspected cases. At times, marrow metastases may have normal serum chemistry and hematologic parameters and may even be missed by bone scans and advanced imaging modalities. This fact highlights the importance of using sensitive techniques for the detection of marrow metastasis. Accurate diagnosis of myelitis by disseminated infections is important for timely management.

Bone marrow aspiration (BMA) is a simple, reliable and rapid method of marrow evaluation. Trephine biopsy provides more comprehensive information regarding the marrow cellularity, architectural patterns and overall hematopoiesis. But biopsy is a painful procedure and its processing takes at least 48-72 hours. So, to perform trephine biopsies in all patients may not be cost effective in terms of clinician and laboratory personnel time, efforts and patient discomfort. Few studies have analyzed the diagnostic accuracy of bone marrow aspirate in comparison with trephine biopsy. Literature on correlation of lymphoma positivity with trephine biopsy length is even sparse. With these considerations, a prospective study was conducted with the objectives of comparing the accuracy of BMA with trephine biopsy done simultaneously in the diagnosis of hematological disorders and to determine the optimum trephine preprocessing length to assess lymphoma infiltration.

Material and Methods. This single institution prospective study was approved by the Institutional Ethics Committee and informed consent was obtained from all the patients. Subject population: From January 2011 to February 2012, 514 patients were recruited in the study and underwent both bone marrow aspirate and biopsy simultaneously. Of these, 65 (12.6%) biopsies were inadequate for assessment and were excluded from analysis. So, final study cohort comprised 449 patients who had undergone both aspirate and biopsy simultaneously. Patient demographic information, clinical history including physical findings, chemo/radiotherapy, complete blood count with peripheral smear findings and indication of bone marrow were collected by one author. Aspirate findings were compared to that of trephine biopsy. Of these, 382 patients were diagnosed or follow up cases of hematolymphoid malignancy and their distribution is shown in table 1. Sixty seven patients presented with pancytopenia/bicytopenia and bone marrow was done to detect the etiology (Figure 1).

Table 1. Distribution of 382 patients of hematological malignancies and proportion of bone marrow positivity

| Provisional Diagnosis | Number | Positive (%) | Negative |
|-----------------------|--------|--------------|----------|
| Non Hodgkin Lymphoma  | 133    | 67 (50.4)    | 66       |
| Hodgkin lymphoma      | 47     | 20 (42.5)    | 27       |
| CMPN*                 | 93     | 81 (87.1)    | 12       |
| Acute leukemia        | 54     | 44 (81.5)    | 10       |
| Multiple myeloma      | 31     | 26 (83.8)    | 5        |
| Metastases            | 23     | 10 (43.5)    | 13       |

* CMPN-Chronic myeloproliferative neoplasm.

Bone marrow aspirate and trephine biopsy: BMA was done using Salah’s needle and 0.25 to 0.5 ml of aspirate was withdrawn with a 20 ml plastic syringe from posterior superior iliac spine. Aspirated material was delivered onto clean glass slides and smears were prepared immediately. After that, trephine biopsy was performed using Jamshidi’s needle through the same incision, approximately 0.5–1 cm away from the site of aspiration to avoid obtaining a hemorrhagic biopsy. Peripheral smears and marrow aspirate smears were stained by Wright’s stain. Trephine biopsies fixed in 10% neutral buffered formalin, were subjected to decalcification in 5.5% EDTA solution for 24 hrs. After decalcification, the preprocessing length of
trephine biopsy was measured with a metric scale and biopsy was routinely processed in automated tissue processor and embedded in paraffin blocks. In cases where a trephine was in several pieces, the total length was recorded. 2-3µm thick sections were cut and stained with hematoxylin & eosin. All the smears and sections were reviewed by two experienced pathologists in consensus. At least three deeper sections, cut at intervals of 0.1-0.2 mm, were examined to assess marrow involvement in patients of lymphoma and suspected metastases. While examining the aspirate, the pathologists were blinded to biopsy findings. BMA and biopsy findings were compared. Wherever indicated, histochemistry was performed. Gömöri’s reticulin and Masson’s trichrome were performed to grade marrow fibrosis according to European Consensus grading system. In cases where tuberculosis was suspected, cold Ziehl Neelson was performed to stain for acid fast bacilli (AFB). PAS was done to look for glycogen and fungal hyphae. For immunohistochemistry, sections on poly-lysine slides were taken and immunohistochemistry was done by standard streptavidin biotinylated peroxidise method.

In suspicious cases of marrow infiltration by lymphoma, panel of antibodies (CD45, CD 20, CD 15, CD 30, CD 3, CD 5) was employed for confirmation and further subtyping. Antibodies against λ and κ light chains were used to establish the monoclonality in neoplastic plasma cells. To confirm nonhematopoietic marrow metastases in suspicious cases, antibodies against cytokeratin, Neuron specific enolase, CD99, S-100 and epithelial membrane antigen were used wherever required. Statistical analysis: Results were statistically analyzed using SPSS software (version 17.0, SPSS, Chicago, Illinois, USA). Concordance rates were calculated between aspirate and biopsy. In groups with sufficient sample size, validity parameters were calculated. Proportion of trephine biopsies showing lymphoma infiltration was plotted on y axis and total preprocessing trephine length on x axis, in increments of 4 mm. Fischer’s exact test was used to analyze the significance in lymphoma positivity between two groups and P value <0.05 was considered statistically significant.

Results. Lymphoma: Lymphomas accounted for 40.1% of all patients. Of these, 73.9% (133/180) patients were of Non Hodgkin Lymphoma (NHL) and Hodgkin lymphoma comprised 26.1%. Of 133 trephines being evaluated for NHL staging, 67 (50.4%) showed marrow infiltration in the form of paratrabecular nodular, interstitial or diffuse pattern (Figure 2). Of these, 20 were SLL/CLL, 15 were follicular and mantle cell, 13 were large cell type and rest could not be further subtyped. 46 out of these 67 aspirates were reported as positive for lymphoma infiltration, 15 were reported as negative and six were inadequate. In 66 cases, both biopsy and aspirate were negative for lymphoma infiltration. Chemotherapy induced changes comprised increased vessel density, necrosis and marked fibrosis of intertrabecular space. These were seen in four trephine biopsies but not in aspirates.

In Hodgkin lymphoma, marrow involvement was seen in 42.5% (20/47) patients. Both biopsy and aspirate were negative for lymphoma in rest 27 patients. Large binucleate cells with moderate amount of cytoplasm, vesicular nucleus and prominent eosinophilic nucleolus (classical Reed Sternberg cells) and mononuclear cells (variant RS) were seen (Figure 3) and confirmed by bright paranuclear positivity for CD 15/ CD30. Focal fibrosis and necrosis was seen in
Figure 4. a) Trephine biopsy of Primary myelofibrosis showing cellular marrow with preponderance of myeloid precursors, atypical megakaryocytes and fibrosis (H&E x200), b) Gomori’s reticulin shows grade 3 fibrosis (Reticulin x200) c) Fibrosis is confirmed by bluestained collagen (Masson trichrome x200)

12 cases. Epithelioid cell granulomas were found in five of them. However, stain for AFB was negative. Only 1 out of 20 aspirate (5%) showed few large atypical mononuclear variants and occasional classical RS cells, suggestive of marrow involvement. 17 aspirates (85%) were reported as negative for marrow infiltration.

Chronic myeloproliferative neoplasm (CMPN): Of 81 patients, 70 were of chronic myeloid leukemia (CML), 9 of primary myelofibrosis (PMF) and 2 of hypereosinophilic syndrome (HES). 28 patients of CML in chronic phase (CP) had minimal fibrosis on biopsy. 30 CML- CP biopsies showed increased number of micromegakaryocytes and grade 2 reticulin fibrosis. 7 of these (23.3%) yielded inadequate aspirates. Trephine biopsy and aspirate were suggestive of blast crises in 10 patients. In 2 patients, peripheral smear and aspirate showed blasts less than 10% suggestive of chronic phase, but trephine biopsy showed focal aggregates of blasts in an entire intertrabecular space, warranting a diagnosis of blast crisis. 9 patients of PMF had cellular marrow with grade 3 reticulin fibrosis and collagenisation (Figure 4). Clusters of atypical megakaryocytes having hyperchromatic bulbous nuclei, were seen adjacent to vascular sinuses. BMA showed dry tap in 7 of these cases after repeated attempts and cellular marrow particles having atypical bizarre megakaryocytes in the remaining 2 cases. Aspirate and biopsy were in agreement in two HES patients.

Acute leukemia: BMA was in agreement with biopsy in 39 patients, but was inadequate in 5 patients who had tightly packed marrow with blasts on biopsy. Nine patients were in complete hematological remission both on aspiration and biopsy.

Metastases: Definitive evidence of marrow metastases was seen in 10/23 patients. Small round cell tumors - Ewing’s/ PNET, neuroblastoma, Wilm’s tumor and retinoblastoma were the primary in children (Figure 5).

Six adult patients (mean age=59yrs) presented with backache, anemia and had multiple lytic lesions in

Figure 5. a) Trephine biopsy shows metastatic neuroblastoma in a child (H&E 400) b) Bone marrow aspirate of the same patient shows metastatic small round cell tumor (Wright stain x400).
vertebral column with differential of metastases and multiple myeloma. Bone marrow examination revealed metastatic adenocarcinoma from prostate, breast, gastrointestinal tract and lung. Of ten marrow metastases, aspirate detected only six. Three aspirates were negative and one was inadequate. In rest 13 suspected patients, both aspirate and biopsy were negative for metastases.

**Multiple myeloma:** Biopsy and aspirate were concordant in 23/26 (88.5%) patients of multiple myeloma. Three aspirates were hypocellular due to fibrosis with focal aggregation of myeloma cells on biopsy sections. On immunohistochemistry, these cells showed evidence of monoclonality by κ or λ light chain restriction (Figure 6). Biopsy and aspirate did not show plasmacytosis in rest 5 patients.

**Pancytopenia/bicytopenia:** In 67 pancytopenic patients, hypercellular marrow was seen in 44, hypocellular marrow in 13 (Figure 7), and marrow was normocellular in 10 patients. Figure 1 shows the spectrum of cases presenting with pancytopenia.

Marrow metastases from neuroblastoma and small cell carcinoma along with secondary myelofibrosis on biopsy presented as pancytopenia, for which marrow was done.

**Comparison of bone marrow aspirate with trephine biopsy:** Concordance rates were calculated between BMA and trephine biopsy (Table 2). In larger subgroups we also calculated validity parameters taking trephine biopsy as gold standard (Table 3).

**Correlation of trephine length with lymphoma positivity:** We had 184 adequate biopsies for lymphoma staging in our study. Of these 49.4% (91) were positive for lymphoma infiltration after examining three sections at deeper levels. The mean length of trephine core was 14 mm, ranging from 1-32 mm. We found that lymphoma positivity showed a rising trend with length of trephine core, with maximum positivity (68.9%) seen in 17-20 mm group, but no further improvement beyond 20 mm (Table 4, Figure 8). Based on this two groups were made, taking 16mm as cut-off. Fischer’s exact test was applied and the difference in both the groups was found to be statistically significant (lymphoma positivity ≤16mm=40.3% and ≥17mm=66.1%, p=0.0011).

**Discussion.** We have evaluated the role of bone marrow aspirate in comparison with trephine biopsy in diagnosis of various hematological disorders. In 28.2% cases aspirate was nondiagnostic, with an overall sensitivity of 71.8%. Jamshidi and Swain reported that in 14-16% patients, aspirate was non diagnostic. Immunohistochemistry was diagnostically helpful in our study in case of NHL, Hodgkin lymphoma and multiple myeloma, where equivocal morphology and low tumor cell burden posed a dilemma. In biopsies with few suspicious cells or crush artifact, it can
Figure 7. a) Bone marrow aspirate from a pancytopenic patient showing hypocellular marrow particles with entangled lymphocytes and plasma cells and occasional erythroid precursors (Wright stain x 400) b) Biopsy shows markedly hypocellular marrow with increased fat spaces, confirming the diagnosis of aplastic anemia (H&E x 100)

Table 2: Concordance between bone marrow aspirate and biopsy

| Diagnosis                      | Positive Biopsy | BMA Not Consistent | BMA Consistent | BMA Inadequate | Concordance rate (%) |
|--------------------------------|-----------------|--------------------|----------------|---------------|----------------------|
| Non Hodgkin Lymphoma           | 71              | 17                 | 48             | 6             | 67.6                 |
| Hodgkin lymphoma               | 20              | 17                 | 1              | 2             | 5.0                  |
| Metastatic solid tumors        | 12              | 3                  | 7              | 2             | 58.3                 |
| Multiple myeloma               | 26              | 2                  | 23             | 1             | 88.5                 |
| CML CP# (Grade 0-1 fibrosis)   | 28              | 0                  | 26             | 2             | 92.8                 |
| CML CP# (Grade 2 fibrosis)     | 30              | 0                  | 23             | 7             | 76.7                 |
| CML- Blast Phase               | 12              | 2                  | 10             | 0             | 83.3                 |
| PMF#                           | 9               | 2                  | 0              | 7             | 0.0                  |
| Hypereosinophilic syndrome     | 2               | 0                  | 2              | 0             | 100                  |
| Acute leukemia                 | 47              | 0                  | 42             | 5             | 89.4                 |
| MDS*                           | 2               | 0                  | 2              | 0             | 100                  |
| Nutritional/ Megaloblastic anemia | 25          | 0                  | 24             | 1             | 96.0                 |
| Aplastic anemia                | 13              | 2                  | 5              | 6             | 38.5                 |
| Granulomatous inflammation     | 4               | 3                  | 0              | 1             | 0.0                  |
| Leishmaniasis                  | 1               | 0                  | 1              | 0             | 100                  |
| ITP**                          | 2               | 0                  | 2              | 0             | 100                  |
| Hemophagocytic syndrome        | 1               | 0                  | 1              | 0             | 100                  |
| Total                          | 305             | 46                 | 219            | 40            | 71.8                 |

* CML-Chronic myeloid leukemia- chronic phase, # PMF-Primary myelofibrosis, *MDS-Myelodysplastic syndrome, ** ITP-Immune thrombocytopenic purpura

Table 3: Validity parameters for bone marrow aspirate

| Diagnosis                   | Sensitivity | Specificity | NPV* | PPV** | Accuracy |
|-----------------------------|-------------|-------------|------|-------|----------|
| NHL                         | 67.7        | 100         | 80.3 | 100   | 77.2     |
| Hodgkin lymphoma            | 5.0         | 100         | 58.7 | 100   | 59.6     |
| Metastases                  | 58.3        | 100         | 72.2 | 100   | 80       |
| Multiple myeloma            | 88.5        | 100         | 62.5 | 100   | 90.3     |
| Acute leukemia              | 89.4        | 100         | 60.7 | 100   | 91.2     |
| CMPN#                       | 75.3        | 100         | 37.5 | 100   | 78.5     |

*CMPN- Chronic myeloproliferative neoplasm, * NPV- Negative predictive value, ** PPV-Positive predictive value

Table 4: Correlation of lymphoma positivity with trephine biopsy length

| Length of trephine biopsy | Total no. of cases | Positive for Lymphoma infiltration | Negative for Lymphoma infiltration | Percentage positivity (%) |
|---------------------------|--------------------|-----------------------------------|-----------------------------------|--------------------------|
| 1-4 mm                    | 8                  | 2                                 | 6                                 | 25                       |
| 5-8 mm                    | 37                 | 12                                | 25                                | 32.4                     |
| 9-12 mm                   | 54                 | 23                                | 31                                | 42.6                     |
| 13-16 mm                  | 20                 | 11                                | 9                                 | 55.0                     |
| 17-20 mm                  | 29                 | 20                                | 9                                 | 68.9                     |
| 21-24 mm                  | 14                 | 9                                 | 5                                 | 64.3                     |
| 25-28 mm                  | 11                 | 7                                 | 4                                 | 63.6                     |
| 29-32 mm                  | 11                 | 7                                 | 4                                 | 63.6                     |
| Total                     | 184                | 91                                | 93                                | 49.4                     |

Mediterr J Hematol Infect Dis 2014; 6: Open Journal System
increase the diagnostic accuracy by unmasking the obscured patterns and morphology.

We found bone marrow aspirate to be 100% specific in most of the disorders, but sensitivity and accuracy depends upon the disease being evaluated. In hematological malignancies, highest sensitivity was seen in acute leukemias (90%), multiple myeloma (88.5%) followed by CMPNs (77.2%). In diffuse marrow pathologies like nutritional anemia, leishmaniasis, ITP and HPS, diagnostic sensitivity of marrow aspirate was 100%. Trephine biopsy did not provide any additional information. Therefore, aspirate may obviate the need of biopsy in such situations.

Frequency of positive BMA in metastatic marrow varies from 23% to 100% in different studies. In our study, 41.7% of aspirates missed marrow metastases, similar to results of previous studies. Focal deposit of nonhematopoietic malignant cells and tumor associated desmoplasia, necrosis are the cause of dry tap on aspiration. According to Chandra et al, aspirate along with imprint smear has similar diagnostic accuracy to trephine biopsy and can avoid the inevitable delay caused by decalcification and routine histopathological processing of the biopsy.7

Overall incidence of marrow involvement by Hodgkin and Non Hodgkin lymphoma was quite high (42.5% and 51.8% respectively) in our study. Various studies have reported marrow infiltration in lymphoma ranging from 27.1 to 55.1%. This variation can be attributed to higher incidence of Hodgkin lymphoma in our population and inclusion of different proportion of patients of early/advanced stage. Only two third of NHL positive marrows were picked up on aspirate and 23.9% were missed on aspiration. BM biopsy renders information which cannot be determined from aspiration, such as spatial distribution and extent of infiltrates, overall cellularity and fibrosis. This also implies that trephine biopsy may be more useful in postchemotherapy patients to assess the residual tumor cell burden and degree of chemotherapy response. Newer techniques like flow cytometry can increase the sensitivity BMA in NHL patients, but could not be evaluated in the present study. Availability of broad panel of antibodies suitable for paraffin-embedded tissues, enables us to perform complete immunophenotyping on trephines and allows classification of lymphoma infiltrates according to established algorithms.4

Our finding that only 5% aspirates were positive, confirm the fact that BMA does not have much role in detecting marrow involvement by Hodgkin disease. Our findings are in agreement with those of Moid and Sharma et al.17,20 Although role of biopsy is controversial especially in stage I and IIA Hodgkin lymphoma, it is still irreplaceable in staging (especially in stage IIB or III cases) and hence alters the treatment.21 We recommend that instead of BMA, trephine biopsy should be done for staging in Hodgkin lymphoma. Necrosis is usually seen post chemotherapy, but we found very high incidence of necrosis and fibrosis (60%) at the time of primary diagnosis. Foci of fibrosis in the absence of classical or variant RS cells, with Hodgkin lymphoma diagnosed elsewhere, are highly suspicious of marrow involvement.22

BMA was 88.5% sensitive in diagnosis of multiple
myeloma. Trephine biopsy helped to identify focal compact masses of plasma cells without any stroma in 7.7% patients which were missed on aspirate. Biopsy is more sensitive method for quantifying plasma cell burden (using CD138 IHC), especially in patients with low percentage of plasma cells on aspirate. However, cytomorphological classification of myeloma is better done on aspirate or imprint (mature, intermediary, immature and plasmablastic types).

In acute leukemia, aspirate had a high accuracy of 91.2%. 10.6% aspirates were inadequate in which trephine biopsy showed near total replacement of marrow by blasts or myeloid precursors and extensive fibrosis. In MDS, aspirate was 100% sensitive but trephine biopsy provided additional information such as detection abnormal localization of immature precursors (ALIP) and aggregates of myeloblasts. Presence of fibrosis or fatty changes in marrow can make accurate disease characterization very difficult or impossible on aspirates. Literature suggests the utility of imprint cytology in providing excellent cytomorphological details in cases of dry tap, but we did not evaluate its role in the present study.

Peripheral smear and BMA may show overlapping findings in CMPNs. Role of trephine biopsy is not only in differentiation of CMPNs, but also to assess the overall marrow cellularity, histotopography and morphology of megakaryocytes and blasts (CD34 positive precursors) and degree of myelofibrosis. Non diagnostic aspirates in CML patients, who had grade 2 marrow fibrosis highlights the importance of trephine biopsy in CML. Also, focal collection of blasts occupying significant intertrabecular space in biopsy clinched the diagnosis of blast crises, irrespective of blast count in peripheral smear and BMA as was seen in our case.

BMA does not have much role in diagnosis of PMF because diffuse osteomyelosclerosis, intrasinusoidal hematopoiesis and vascular proliferation, which are characteristic of fibrotic PMF, can be confirmed and graded on biopsy sections only.

Megaloblastic anemia was the most common (37%) cause of pancytopenia in our study. High incidence of megaloblastic anemia can be explained by prevalent malnutrition and infectious diseases, seen in tropical country as ours. Aplastic anemia was the etiology in 19%, but aspirate was suggestive in only 38.5% cases. Trephine biopsy gives the qualitative and quantitative assessment of cellularity, therefore, is confirmatory in the diagnosis of aplastic anemia and overcomes the limitation of dry tap. In addition, biopsy can provide the number and distribution of megakaryocytes, lymphocytes, plasma cells in marrow and blasts, all of which are prognostic markers required in follow up of aplastic anemia.

Rarely, Hodgkin and NHL can present as pan or bicytopenia without any evidence of lymphadenopathy/ hepatosplenomegaly as was seen in 5.9% cases. Disseminated tuberculosis was another important cause of pancytopenia in our population (5.9%). Aspirate is not useful in diagnosis of granulomatous myelitis as seen in our study, confirming the findings of Toi et al. Granulomatous response can be seen in tuberculosis, Hodgkin lymphoma, NHL, fungal infections and sarcoidosis. Though AFB stain was positive in 50% cases, presence of discrete epithelioid cell caseating granulomas and clinical findings were suggestive of disseminated tuberculosis in all of them (Figure 9). Very rarely, metastases can present with pancytopenia as was seen in neuroblastoma and small cell carcinoma (2.9% cases).

![Figure 9. Trephine biopsy shows epithelioid cell granuloma with central necrosis (H&Ex100)](image_url)

Amount of assessable marrow included in the biopsy specimen is of more importance than the total length. Logically, the likelihood of lymphoma positivity should rise concomitant with the length of interpretable biopsy specimen and examination of serial deeper sections. However, in our study no diagnostic gain was achieved above a length of 20 mm, with maximum percentage positivity (68.9%) obtained in biopsies 17-20 mm long. Trephine biopsies ≥ 17mm had significantly higher lymphoma positivity as compared to those of ≤16mm. The National Cancer Institute has recommended a trephine length of ≥20 mm for NHL staging. Campbell et al has supported this recommendation and emphasized the role of examining multiple sections. Bain suggested a minimum trephine length of 16 mm, based on the findings of Bishop et al. in which a plateau was achieved in the rate of detection of metastatic tumour after trephine length exceeded 16 mm. We found
preprocessing trephine biopsy 17-20 mm long, along with examination of multiple deeper sections optimal for detection of lymphoma infiltration.

There are few limitations of our study. We did not evaluate the role of flow cytometry and touch imprint cytology in our study, both of which can increase the diagnostic accuracy. There were many subgroups in our study, some of which had small sample size. This is because we did not focus on any single disease, rather prospectively included all the patients presenting to us over a period of one year.

Conclusion. Bone marrow aspirate is a simple and rapid alternative to biopsy, and has high specificity and positive predictive value. Aspirate is especially useful for acute leukemia, multiple myeloma, nutritional anemia, immune thrombocytopenias and other diffuse marrow disorders, where sensitivity and NPV are also equally good. Aspirate has a very limited role as far as Hodgkin lymphoma, granulomatous myelitis, aplastic anemia and myelofibrosis are concerned, making biopsy mandatory. In NHL, metastases and CMPNs, aspirate alone is insufficient and biopsy is complementary. Biopsy provides additional information like marrow fibrosis, pattern of marrow involvement, topographical alterations of hematopoietic cells, and postchemotherapy changes, which are prognostically useful. Trephine biopsies 17-20 mm long, examined at multiple deeper levels, had maximum proportion of lymphoma positivity and are optimal for assessing lymphoma infiltration. Biopsies longer than 20 mm don’t offer any added advantage.

References:

1. Toi PCh, Varghese RG, Rai R. Comparative evaluation of simultaneous bone marrow aspiration and bone marrow biopsy: an institutional experience. Indian J Hematol Blood Transfus. 2010; 26: 41-4. http://dx.doi.org/10.1007/s12288-010-0010-x PMid:21629634 PMCid:PMC3002664
2. Riley RS, Hogan TF, Pevot DR, et al. A pathologist’s perspective on bone marrow aspiration and biopsy: Performing a bone marrow examination. J Clin Lab Anal. 2004; 18: 70-9. http://dx.doi.org/10.1002/jcla.20008 PMid:15065211
3. Banyas M, Solomayer EF, Becker S et al. Disseminated tumor cells in bone marrow may affect prognosis of patients with gynaecological malignancies. Int J Gynecol Cancer. 2009; 19: 948-52. http://dx.doi.org/10.1111/j.1525-1991.2008.00822.x PMid:19574790
4. Fend F, Kremer M. Diagnosis and classification of malignant lymphoma and related entities in the bone marrow trephine biopsy. Pathobiology. 2007; 74: http://dx.doi.org/10.1159/000101712 PMid:15787884
5. Ozkalemkas F, Ali R, Ozkocaman V et al. The bone marrow aspirate and biopsy in the diagnosis of unsuspected nonhematologic malignancy: a clinical study of 19 cases. BMC Cancer. 2005; 5: 144. http://dx.doi.org/10.1186/1471-2407-5-144 PMid:16262899 PMCid:PMC310632
6. Yuka Y, Yoshishiro N, Koiku Y, Katashi S, Motoomi O. Comparing whole body FDG-PET and bone scan to detect bone metastasis in malignant tumor patients. International Congress Series. 2004; 1264: 239-42.
7. Chandra S, Chandra H. Comparison of bone marrow aspirate cytology, touch imprint cytology and trephine biopsy for bone marrow evaluation. Hematol Rep. 2011; 3: e22. PMid:22593814 PMCid:PMC3269795
8. Varma N, Dash S, Sarode R, Marwaha N. Relative efficacy of bone marrow trephine biopsy sections as compared to trephine imprints and aspiration smears in routine hematological practice. Indian J Pathol Microbiol. 1993; 36: 215-26. PMid:8300166
9. Nanda A, Basu S, Marwaha N. Bone marrow trephine biopsy as an adjunct to bone marrow aspiration. J Assoc Physicians India. 2002; 50: 893-5. PMid:12126342
10. Sabharwal BD, Malhotra V, Aruna S, Grewal R. Comparative evaluation of bone marrow aspirate smear technique, imprints and biopsy sections. J Postgrad Med. 1990; 36: 194-8. PMid:2132243
11. Cheson BD, Horning SJ, Coiffrer B et al. Report of an international workshop to standardize response criteria for non-Hodgkin lymphomas. J Clin Oncol. 1999; 17: 1244-53. PMid:10561185
12. Campbell JK, Matthews JP, Seymour JF, Wolf MM, Juneja SK. Australasian Leukaemia Lymphoma Group. Optimum trephine length in the assessment of bone marrow involvement in patients with diffuse large cell lymphoma. Ann Oncol. 2003; 14: 273-6. http://dx.doi.org/10.1093/annonc/mdg055 PMid:12562655
13. Thiele J, Kvassnica HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Hematologica. 2005; 90: 1128-32.
14. Jamshidi K, Swain WR. Bone marrow biopsy with unaltered architecture: a new biopsy device. J Clin Lab Med. 1971; 77: 335-41
15. Atac B, Lawrence C, Goldberg SN. Metastatic tumor: the complementary role of the marrow aspirate and biopsy. Am J Med Sci. 1991; 302: 211-3. http://dx.doi.org/10.1097/00000441-199101000-00005 PMid:1928232
16. Chandra S, Chandra H, Saini S. Bone marrow metastasis by solid tumors—probable hematological indicators and comparison of bone marrow aspirate, touch imprint and trephine biopsy. Hematology. 2010; 15: 368-72. http://dx.doi.org/10.1179/1742535310X12467863621001 PMid:20863433
17. Mod F, Depalma L. Comparison of relative value of bone marrow aspirates and bone marrow trephine biopsies in the diagnosis of solid tumour metastasis and Hodgkin Lymphoma. Arch Pathol Lab Med. 2005; 129: 497-501. PMid:15794673
18. Sharma S, Murari M. Bone marrow involvement by metastatic solid tumors. Indian J Pathol Microbiol. 2003; 46: 382-4. PMid:15025279
19. Kumar S, Rau AR, Naik R, et al. Bone marrow biopsy in non-Hodgkin lymphoma: a morphological study. Indian J Pathol Microbiol. 2009; 52: 332-8. http://dx.doi.org/10.4103/0377-4929.54977 PMid:19674119
20. Sharma S, Ahuja A, Murari M. Bone marrow biopsy in Hodgkin’s disease. Indian J Pathol Microbiol 2004; 47: 364-6 PMid:16295425
21. Franco V, Tripodo C, Rizzo A, Stella M, Florena AM. Bone marrow biopsy in Hodgkin’s lymphoma. Eur J Hematol. 2004; 73: 149-55. http://dx.doi.org/10.1111/j.1600-0609.2004.00292.x PMid:15287910
22. Kar R, Dutta S, Tyagi C. Clinically unsuspected Hodgkin’s lymphoma diagnosed primarily from bone marrow trephine biopsy: report of six cases. Indian J Pathol Microbiol. 2008; 51: 186-9. http://dx.doi.org/10.4103/0377-4929.41675 PMid:18603677
23. Sultar S, Babarovic E, Valkovic T, et al. Combined evaluation of bone marrow aspirate and biopsy is superior in the prognosis of multiple myeloma Diagnostic Pathology. 2010; 5: 30. http://dx.doi.org/10.1186/1746-1596-5-30 PMid:20482792 PMCid:PMC2883968
24. Brunning R, McKenna RW: Atlas of tumor pathology. Tumors of the bone marrow Washington, DC: Armed Forces Institute of Pathology, American Registry of Pathology 1994: 323-367.
25. Orazi A. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases. Pathobiology. 2007; 74: 97-114. http://dx.doi.org/10.1159/000101709 PMid:17587881
26. Vardiman JW, Melo JV, Baccaiani M, Thiele J. Chronic myelogenous leukemia, BCR-ABL1 positive. In: Swerdlow SH
Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, eds. WHO classification of tumors of hematoopoietic and lymphoid tissues. 4th Ed. Lyon, International Agency for Research on Cancer, 2008; 32-7.
27. Buhr T, Büsche G, Choritz H, Länger F, Kreipe H. Evolution of Myelofibrosis in Chronic Idiopathic Myelofibrosis as Evidenced in Sequential Bone Marrow Biopsy Specimens. Am J Clin Pathol. 2003; 119: 152-8. http://dx.doi.org/10.1309/PTVGB3DXB8A8M7KD PMid:12520711
28. Milosevic R, Jankovic G, Antonijevic N, Jovanovic V, Babic D, Colovic M. Histopathologic characteristics of bone marrow in patients with aplastic anemia. Srp Arh Celok Lek. 2000; 128: 200-4. PMid:11089422
29. Bhargava V, Farhi DC. Bone marrow granulomas, clinicopathological findings in 72 cases and review of the literature. Hematol Pathol. 1988; 2: 43-50. PMid:3069830
30. Bain B. Bone marrow trephine biopsy. J Clin Path. 2001; 54: 737-42. http://dx.doi.org/10.1136/jcp.54.10.737 PMid:11577117
31. Bishop PW, McNally K, Harris M. Audit of bone marrow trephines. J Clin Path. 1992; 45: 1105-8. http://dx.doi.org/10.1136/jcp.45.12.1105 PMid:1479037